glp-1 compounds Peptide sequences and molecular structures of FDA approved RAs Navigating GLP-1 Antagonist Shortages and

Activation of D1 receptors in the kidneys and vasculature leads to vasodilation, which can lower blood pressure

A population-based study of 467 matched pairs of GLP-1 users and non-users with type 2 diabetes and liver cirrhosis found GLP-1 use associated with lower risks of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure

Whereas genetic or pharmacologic inhibition of the necroptosis axis prevented activation of necroinflammation and subsequent development of renal fibrogenesis (Jiang et al., 2022

The markedly reduced risk here for alcohol use disorder patients taking GLP-1 agonists suggests that this class of drugs might actually be more effective than the current crop of officially approved medications for treating alcohol addiction